You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBepridil
Accession NumberDB01244  (APRD00727)
TypeSmall Molecule
GroupsApproved, Withdrawn
DescriptionA long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. [PubChem] It is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes).
Structure
Thumb
Synonyms
Bepadin
Bepridil
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AngoprilNot Available
CordiumNot Available
VascorNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Bepridil hydrochloride
74764-40-2
Thumb
  • InChI Key: UEECHQPWQHYEDE-UHFFFAOYSA-N
  • Monoisotopic Mass: 420.2543561
  • Average Mass: 421.02
DBSALT001436
Categories
UNII755BO701MA
CAS number64706-54-3
WeightAverage: 366.5396
Monoisotopic: 366.26711372
Chemical FormulaC24H34N2O
InChI KeyUIEATEWHFDRYRU-UHFFFAOYSA-N
InChI
InChI=1S/C24H34N2O/c1-21(2)19-27-20-24(25-15-9-10-16-25)18-26(23-13-7-4-8-14-23)17-22-11-5-3-6-12-22/h3-8,11-14,21,24H,9-10,15-20H2,1-2H3
IUPAC Name
N-benzyl-N-[3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl]aniline
SMILES
CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1
Pharmacology
IndicationFor the treatment of hypertension, and chronic stable angina (classic effort-associated angina).
Structured Indications Not Available
PharmacodynamicsBepridil is a calcium channel blocker that has well characterized anti-anginal properties and known but poorly characterized type 1 anti-arrhythmic and anti-hypertensive properties. It is not related chemically to other calcium channel blockers such as diltiazem hydrochloride, nifedipine and verapamil hydrochloride.
Mechanism of actionBepridil has inhibitory effects on both the slow calcium (L-type) and fast sodium inward currents in myocardial and vascular smooth muscle, interferes with calcium binding to calmodulin, and blocks both voltage and receptor operated calcium channels. Bepridil inhibits the transmembrane influx of calcium ions into cardiac and vascular smooth muscle. This has been demonstrated in isolated myocardial and vascular smooth muscle preparations in which both the slope of the calcium dose response curve and the maximum calcium-induced inotropic response were significantly reduced by bepridil. In cardiac myocytes in vitro, bepridil was shown to be tightly bound to actin. Bepridil regularly reduces heart rate and arterial pressure at rest and at a given level of exercise by dilating peripheral arterioles and reducing total peripheral resistance (afterload) against which the heart works.
TargetKindPharmacological actionActionsOrganismUniProt ID
Voltage-dependent P/Q-type calcium channel subunit alpha-1AProteinyes
inhibitor
HumanO00555 details
Voltage-dependent T-type calcium channel subunit alpha-1HProteinyes
inhibitor
HumanO95180 details
Voltage-dependent calcium channel subunit alpha-2/delta-2Proteinyes
inhibitor
HumanQ9NY47 details
Sodium/potassium-transporting ATPase subunit alpha-1Proteinunknown
inhibitor
HumanP05023 details
Potassium voltage-gated channel subfamily KQT member 1Proteinunknown
inhibitor
HumanP51787 details
Troponin C, slow skeletal and cardiac musclesProteinunknown
other
HumanP63316 details
CalmodulinProteinunknown
binder
HumanP62158 details
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BProteinunknown
inhibitor
HumanQ01064 details
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AProteinunknown
inhibitor
HumanP54750 details
Related Articles
AbsorptionRapidly and completely absorbed after oral administration.
Volume of distributionNot Available
Protein binding99%
Metabolism

Hepatic.

Route of eliminationNot Available
Half life24-50 hours
ClearanceNot Available
ToxicityThere has been one experience with overdosage in which a patient inadvertently took a single dose of 1600 mg of bepridil. The patient was observed for 72 hours in intensive care, but no significant adverse experiences were noted.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Bepridil.Experimental
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Bepridil.Vet Approved
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Bepridil.Experimental
AbirateroneThe serum concentration of Bepridil can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Bepridil.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Bepridil.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Bepridil is combined with Acetazolamide.Approved, Vet Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Bepridil.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Bepridil.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Bepridil.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Bepridil.Experimental
AlfuzosinAlfuzosin may increase the hypotensive activities of Bepridil.Approved, Investigational
AliskirenBepridil may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Bepridil.Approved, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Bepridil.Approved, Withdrawn
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Bepridil.Approved, Investigational
AmifostineBepridil may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Bepridil.Approved
AmiodaroneThe metabolism of Bepridil can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Bepridil.Approved
AmlodipineAmlodipine may increase the hypotensive activities of Bepridil.Approved
AmobarbitalThe metabolism of Bepridil can be increased when combined with Amobarbital.Approved, Illicit
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Bepridil.Approved
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Bepridil.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Bepridil.Approved
AN2690The risk or severity of adverse effects can be increased when AN2690 is combined with Bepridil.Investigational
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Bepridil.Approved, Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Bepridil.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Bepridil.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Bepridil.Approved
AripiprazoleAripiprazole may increase the hypotensive activities of Bepridil.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Bepridil.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Bepridil.Approved, Investigational
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Bepridil.Approved
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Bepridil.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Bepridil.Approved
AtomoxetineThe metabolism of Bepridil can be decreased when combined with Atomoxetine.Approved
AtosibanThe risk or severity of adverse effects can be increased when Bepridil is combined with Atosiban.Approved
Atracurium besylateBepridil may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Bepridil.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Bepridil.Approved
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Bepridil.Experimental
BarbexacloneBarbexaclone may increase the hypotensive activities of Bepridil.Experimental
BarbitalThe metabolism of Bepridil can be increased when combined with Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Bepridil.Approved
BenazeprilBenazepril may increase the hypotensive activities of Bepridil.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Bepridil.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Bepridil.Withdrawn
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Bepridil.Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Bepridil.Approved, Vet Approved
BetaxololThe metabolism of Bepridil can be decreased when combined with Betaxolol.Approved
BethanidineBethanidine may increase the hypotensive activities of Bepridil.Approved
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Bepridil.Approved
BimatoprostBimatoprost may increase the hypotensive activities of Bepridil.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Bepridil.Approved
BoceprevirThe serum concentration of Bepridil can be increased when it is combined with Boceprevir.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bepridil is combined with Bortezomib.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Bepridil.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Bepridil.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Bepridil.Approved
BretyliumBretylium may increase the hypotensive activities of Bepridil.Approved
BrimonidineBrimonidine may increase the hypotensive activities of Bepridil.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Bepridil.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Bepridil.Approved, Investigational
BucindololBucindolol may increase the hypotensive activities of Bepridil.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Bepridil.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bepridil is combined with Bupivacaine.Approved, Investigational
BupranololBepridil may increase the hypotensive activities of Bupranolol.Approved
BupropionThe metabolism of Bepridil can be decreased when combined with Bupropion.Approved
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Bepridil.Approved
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Bepridil.Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Bepridil.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Bepridil.Approved
CalciumThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium.Nutraceutical
Calcium AcetateThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium Acetate.Approved
Calcium carbonateThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium carbonate.Approved
Calcium ChlorideThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium Chloride.Approved
Calcium citrateThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium citrate.Approved
Calcium glubionateThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Bepridil.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Bepridil.Approved
CandesartanCandesartan may increase the hypotensive activities of Bepridil.Approved
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Bepridil.Withdrawn
CandoxatrilCandoxatril may increase the hypotensive activities of Bepridil.Experimental
CaptoprilCaptopril may increase the hypotensive activities of Bepridil.Approved
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Bepridil.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Bepridil is combined with Carbetocin.Approved
CarbomycinThe metabolism of Bepridil can be decreased when combined with Carbomycin.Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Bepridil.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Bepridil.Withdrawn
CarteololCarteolol may increase the hypotensive activities of Bepridil.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Bepridil.Approved, Investigational
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Bepridil.Approved
CelecoxibThe metabolism of Bepridil can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololBepridil may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Bepridil.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Bepridil.Withdrawn
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Bepridil.Approved
ChloroquineThe metabolism of Bepridil can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Bepridil.Approved, Vet Approved
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Bepridil.Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Bepridil.Approved, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Bepridil.Approved
CholecalciferolThe metabolism of Bepridil can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Bepridil.Approved, Investigational
CilazaprilBepridil may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Bepridil is combined with Cilnidipine.Approved
CimetidineThe serum concentration of Bepridil can be increased when it is combined with Cimetidine.Approved
CinacalcetThe metabolism of Bepridil can be decreased when combined with Cinacalcet.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Bepridil.Approved, Investigational
CisaprideCisapride may increase the QTc-prolonging activities of Bepridil.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Bepridil.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Bepridil.Approved
ClarithromycinThe metabolism of Bepridil can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Bepridil can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Bepridil.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Bepridil.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Bepridil is combined with Clofarabine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Bepridil.Approved, Investigational
ClomipramineThe metabolism of Bepridil can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Bepridil.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Bepridil.Approved, Nutraceutical
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Bepridil.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Bepridil.Approved
CobicistatThe serum concentration of Bepridil can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Bepridil.Approved
CocaineThe metabolism of Bepridil can be decreased when combined with Cocaine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Bepridil.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Bepridil is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Bepridil.Approved
CordycepinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Bepridil.Investigational
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Bepridil.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Bepridil.Approved
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Bepridil.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Bepridil.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Bepridil.Approved
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Bepridil.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Bepridil.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Bepridil.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Bepridil.Investigational
DarifenacinThe metabolism of Bepridil can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Bepridil can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Bepridil.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Bepridil.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Bepridil.Approved
Decanoic AcidThe risk or severity of adverse effects can be increased when Decanoic Acid is combined with Bepridil.Experimental
DelavirdineThe metabolism of Bepridil can be decreased when combined with Delavirdine.Approved
DeserpidineBepridil may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Bepridil is combined with Desflurane.Approved
DesipramineThe metabolism of Bepridil can be decreased when combined with Desipramine.Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Bepridil.Approved, Investigational, Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Bepridil.Approved, Vet Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Bepridil.Approved, Illicit, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Bepridil.Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Bepridil.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Bepridil.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Bepridil.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Bepridil.Approved
DihydralazineBepridil may increase the hypotensive activities of Dihydralazine.Investigational
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Bepridil.Illicit
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Bepridil.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Bepridil.Approved
DiphenhydramineThe metabolism of Bepridil can be decreased when combined with Diphenhydramine.Approved
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Bepridil.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Bepridil.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Bepridil.Approved, Investigational, Vet Approved
DorzolamideDorzolamide may increase the hypotensive activities of Bepridil.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Bepridil.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Bepridil.Approved, Investigational
DronedaroneThe metabolism of Bepridil can be decreased when combined with Dronedarone.Approved
DuloxetineBepridil may increase the orthostatic hypotensive activities of Duloxetine.Approved
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Bepridil.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Bepridil.Approved
EfavirenzThe serum concentration of Bepridil can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Bepridil.Approved
EfonidipineBepridil may increase the hypotensive activities of Efonidipine.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Bepridil.Approved, Investigational
EliglustatThe metabolism of Bepridil can be decreased when combined with Eliglustat.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Bepridil.Approved
EnalaprilEnalapril may increase the hypotensive activities of Bepridil.Approved, Vet Approved
EnalaprilatBepridil may increase the hypotensive activities of Enalaprilat.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Bepridil.Approved, Investigational
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Bepridil.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Bepridil.Approved
EprosartanEprosartan may increase the hypotensive activities of Bepridil.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Bepridil.Approved, Investigational
ErythromycinThe metabolism of Bepridil can be decreased when combined with Erythromycin.Approved, Vet Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Bepridil.Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Bepridil.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Bepridil.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Bepridil.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Bepridil.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Bepridil.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Bepridil.Approved
EtravirineThe serum concentration of Bepridil can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Bepridil.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Bepridil.Approved
FelodipineFelodipine may increase the hypotensive activities of Bepridil.Approved, Investigational
FenoldopamFenoldopam may increase the hypotensive activities of Bepridil.Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Bepridil.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Bepridil.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Bepridil.Approved
FimasartanThe risk or severity of adverse effects can be increased when Bepridil is combined with Fimasartan.Approved
FluconazoleThe serum concentration of Bepridil can be increased when it is combined with Fluconazole.Approved
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Bepridil.Approved
FluoxetineThe metabolism of Bepridil can be decreased when combined with Fluoxetine.Approved, Vet Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Bepridil.Approved
FluvoxamineThe metabolism of Bepridil can be decreased when combined with Fluvoxamine.Approved, Investigational
FosinoprilFosinopril may increase the hypotensive activities of Bepridil.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Bepridil.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Bepridil.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Bepridil.Approved, Vet Approved
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Bepridil.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Bepridil.Approved
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Bepridil.Experimental
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Bepridil.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Bepridil.Withdrawn
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Bepridil.Approved, Vet Approved
GuanabenzGuanabenz may increase the hypotensive activities of Bepridil.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Bepridil.Approved
GuanethidineGuanethidine may increase the hypotensive activities of Bepridil.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Bepridil.Approved, Investigational
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Bepridil.Approved
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Bepridil.Approved, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Bepridil is combined with Halothane.Approved, Vet Approved
HexamethoniumBepridil may increase the hypotensive activities of Hexamethonium.Experimental
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Bepridil.Approved
HexobarbitalThe metabolism of Bepridil can be increased when combined with Hexobarbital.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Bepridil.Approved
HydralazineBepridil may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Bepridil.Approved, Vet Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Bepridil.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Bepridil.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Bepridil.Approved
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Bepridil.Approved
IloprostIloprost may increase the hypotensive activities of Bepridil.Approved, Investigational
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Bepridil.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Bepridil is combined with Imidapril.Investigational
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Bepridil.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Bepridil.Approved
IndapamideIndapamide may increase the hypotensive activities of Bepridil.Approved
IndenololBepridil may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Bepridil.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Bepridil.Approved, Investigational
IndoraminBepridil may increase the hypotensive activities of Indoramin.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Bepridil.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Bepridil.Withdrawn
IrbesartanIrbesartan may increase the hypotensive activities of Bepridil.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Bepridil.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Bepridil.Approved
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Bepridil.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Bepridil is combined with Isoflurane.Approved, Vet Approved
IsoniazidThe metabolism of Bepridil can be decreased when combined with Isoniazid.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Bepridil.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Bepridil.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Bepridil.Approved, Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Bepridil.Approved
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Bepridil.Approved, Investigational
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Bepridil.Approved, Vet Approved
JosamycinThe metabolism of Bepridil can be decreased when combined with Josamycin.Approved
KetanserinBepridil may increase the hypotensive activities of Ketanserin.Investigational
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Bepridil.Approved
KetoconazoleThe risk or severity of adverse effects can be increased when Ketoconazole is combined with Bepridil.Approved, Investigational
KitasamycinThe metabolism of Bepridil can be decreased when combined with Kitasamycin.Experimental
LabetalolLabetalol may increase the hypotensive activities of Bepridil.Approved
LacidipineBepridil may increase the hypotensive activities of Lacidipine.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Bepridil.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Bepridil.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Bepridil.Approved, Investigational
LatanoprostLatanoprost may increase the hypotensive activities of Bepridil.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Bepridil.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Bepridil.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Bepridil.Approved
LercanidipineLercanidipine may increase the hypotensive activities of Bepridil.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Bepridil.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Bepridil.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Bepridil is combined with Levobupivacaine.Approved
LevodopaBepridil may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Bepridil.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Bepridil.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Bepridil is combined with Levosimendan.Approved, Investigational
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Bepridil.Approved
LisinoprilLisinopril may increase the hypotensive activities of Bepridil.Approved, Investigational
LofexidineBepridil may increase the hypotensive activities of Lofexidine.Approved, Investigational
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Bepridil.Approved
LopinavirThe metabolism of Bepridil can be decreased when combined with Lopinavir.Approved
LorcaserinThe metabolism of Bepridil can be decreased when combined with Lorcaserin.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Bepridil.Approved
LumefantrineThe metabolism of Bepridil can be decreased when combined with Lumefantrine.Approved
MacitentanBepridil may increase the hypotensive activities of Macitentan.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Bepridil is combined with Magnesium hydroxide.Approved
Magnesium oxideThe risk or severity of adverse effects can be increased when Bepridil is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Bepridil is combined with Magnesium salicylate.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Bepridil is combined with Magnesium Sulfate.Approved, Vet Approved
ManidipineBepridil may increase the hypotensive activities of Manidipine.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Bepridil.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Bepridil.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Bepridil.Approved
MethadoneThe metabolism of Bepridil can be decreased when combined with Methadone.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Bepridil.Approved
MethohexitalThe metabolism of Bepridil can be increased when combined with Methohexital.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Bepridil.Approved
MethotrimeprazineThe metabolism of Bepridil can be decreased when combined with Methotrimeprazine.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Bepridil.Approved
MethyldopaMethyldopa may increase the hypotensive activities of Bepridil.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Bepridil.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Bepridil.Approved, Investigational
MethylphenobarbitalThe metabolism of Bepridil can be increased when combined with Methylphenobarbital.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Bepridil.Approved, Vet Approved
MetipranololMetipranolol may increase the hypotensive activities of Bepridil.Approved
MetolazoneMetolazone may increase the hypotensive activities of Bepridil.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Bepridil.Approved, Investigational
MetyrosineBepridil may increase the hypotensive activities of Metyrosine.Approved
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Bepridil.Experimental
MibefradilBepridil may increase the hypotensive activities of Mibefradil.Withdrawn
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Bepridil.Approved, Investigational
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Bepridil.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Bepridil.Approved, Illicit
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Bepridil.Approved
MinaprineMinaprine may increase the hypotensive activities of Bepridil.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Bepridil.Approved
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Bepridil.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Bepridil.Approved, Investigational
MivacuriumBepridil may increase the neuromuscular blocking activities of Mivacurium.Approved
MoclobemideMoclobemide may increase the hypotensive activities of Bepridil.Approved
MoexiprilMoexipril may increase the hypotensive activities of Bepridil.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Bepridil.Approved
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Bepridil.Vet Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Bepridil.Approved, Investigational
MoxonidineBepridil may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Bepridil.Approved, Investigational
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Bepridil.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Bepridil is combined with Nabilone.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Bepridil.Approved
NafcillinThe metabolism of Bepridil can be increased when combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Bepridil.Approved
NaftopidilBepridil may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Bepridil.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Bepridil.Approved, Vet Approved
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Bepridil.Approved
NebivololBepridil may increase the hypotensive activities of Nebivolol.Approved, Investigational
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Bepridil.Approved
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Bepridil.Approved, Investigational
NevirapineThe metabolism of Bepridil can be decreased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Bepridil.Withdrawn
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Bepridil.Approved
NicorandilNicorandil may increase the hypotensive activities of Bepridil.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Bepridil.Approved
NiguldipineBepridil may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Bepridil.Approved, Investigational
NilvadipineBepridil may increase the hypotensive activities of Nilvadipine.Approved
NimodipineNimodipine may increase the hypotensive activities of Bepridil.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Bepridil.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Bepridil.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Bepridil.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Bepridil is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Bepridil.Approved, Investigational
NitroprussideBepridil may increase the hypotensive activities of Nitroprusside.Approved
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Bepridil.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Bepridil.Approved
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Bepridil.Approved, Vet Approved
ObinutuzumabBepridil may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Bepridil.Withdrawn
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Bepridil.Approved, Investigational
OleandomycinThe metabolism of Bepridil can be decreased when combined with Oleandomycin.Vet Approved
OlmesartanOlmesartan may increase the hypotensive activities of Bepridil.Approved, Investigational
OmapatrilatOmapatrilat may increase the hypotensive activities of Bepridil.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Bepridil.Approved
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Bepridil.Approved
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Bepridil.Approved
OxprenololBepridil may increase the hypotensive activities of Oxprenolol.Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Bepridil.Approved, Vet Approved
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Bepridil.Investigational
PanobinostatThe serum concentration of Bepridil can be increased when it is combined with Panobinostat.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Bepridil.Approved
PargylinePargyline may increase the hypotensive activities of Bepridil.Approved
ParoxetineThe metabolism of Bepridil can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Bepridil.Approved
Peginterferon alfa-2bThe serum concentration of Bepridil can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololBepridil may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Bepridil.Approved
PentobarbitalThe metabolism of Bepridil can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Bepridil.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Bepridil.Approved, Investigational
PerindoprilPerindopril may increase the hypotensive activities of Bepridil.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Bepridil.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Bepridil.Withdrawn
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Bepridil.Approved
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Bepridil.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Bepridil.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Bepridil.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Bepridil.Approved, Vet Approved
PinacidilBepridil may increase the hypotensive activities of Pinacidil.Withdrawn
PindololPindolol may increase the hypotensive activities of Bepridil.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Bepridil is combined with Pipamperone.Approved
PirlindolePirlindole may increase the hypotensive activities of Bepridil.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Bepridil.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Bepridil.Withdrawn
PolythiazideBepridil may increase the hypotensive activities of Polythiazide.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Bepridil.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Bepridil.Approved
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Bepridil.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Bepridil is combined with Pramipexole.Approved, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Bepridil.Approved
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Bepridil.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Bepridil.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Bepridil.Approved, Vet Approved
PrimidoneThe metabolism of Bepridil can be increased when combined with Primidone.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Bepridil.Approved, Vet Approved
PromazineThe metabolism of Bepridil can be decreased when combined with Promazine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Bepridil is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Bepridil.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Bepridil.Approved
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Bepridil.Approved
QuinaprilQuinapril may increase the hypotensive activities of Bepridil.Approved, Investigational
QuinidineThe metabolism of Bepridil can be decreased when combined with Quinidine.Approved
QuinineQuinine may increase the hypotensive activities of Bepridil.Approved
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Bepridil.Experimental
RamiprilRamipril may increase the hypotensive activities of Bepridil.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Bepridil.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Bepridil.Approved, Investigational
RapacuroniumBepridil may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineRasagiline may increase the hypotensive activities of Bepridil.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Bepridil is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Bepridil.Approved
RescinnamineBepridil may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Bepridil.Approved
RifabutinThe serum concentration of Bepridil can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Bepridil can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Bepridil can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Bepridil.Approved, Investigational
RilmenidineBepridil may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatBepridil may increase the hypotensive activities of Riociguat.Approved
RisperidoneBepridil may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe metabolism of Bepridil can be decreased when combined with Ritonavir.Approved, Investigational
RituximabBepridil may increase the hypotensive activities of Rituximab.Approved
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Bepridil.Approved
RolapitantThe metabolism of Bepridil can be decreased when combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Bepridil.Approved, Investigational
RopiniroleThe metabolism of Bepridil can be decreased when combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Bepridil is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Bepridil is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Bepridil is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Bepridil.Withdrawn
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Bepridil.Experimental
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Bepridil.Approved, Vet Approved
SaprisartanBepridil may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirBepridil may increase the arrhythmogenic activities of Saquinavir.Approved, Investigational
SecobarbitalThe metabolism of Bepridil can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Bepridil.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Bepridil.Approved
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Bepridil.Approved
SertralineThe metabolism of Bepridil can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Bepridil is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Bepridil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Bepridil.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Bepridil.Approved
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Bepridil.Experimental
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Bepridil.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Bepridil.Approved, Investigational
SitaxentanBepridil may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Bepridil is combined with Sodium Nitrite.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Bepridil.Approved
SolithromycinThe metabolism of Bepridil can be decreased when combined with Solithromycin.Investigational
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Bepridil.Approved, Investigational
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Bepridil.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Bepridil.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Bepridil.Experimental
SpiraprilBepridil may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Bepridil.Approved
StiripentolThe metabolism of Bepridil can be decreased when combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Bepridil is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Bepridil is combined with Sufentanil.Approved, Investigational
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Bepridil.Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Bepridil.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Bepridil.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Bepridil.Approved
TamsulosinTamsulosin may increase the hypotensive activities of Bepridil.Approved, Investigational
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Bepridil.Experimental
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Bepridil.Approved
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Bepridil.Approved
TelaprevirThe risk or severity of adverse effects can be increased when Telaprevir is combined with Bepridil.Approved
TelithromycinThe metabolism of Bepridil can be decreased when combined with Telithromycin.Approved
TelmisartanTelmisartan may increase the hypotensive activities of Bepridil.Approved, Investigational
TemocaprilBepridil may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Bepridil.Approved
TerazosinTerazosin may increase the hypotensive activities of Bepridil.Approved
TerbinafineThe metabolism of Bepridil can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Bepridil.Approved
TerlipressinBepridil may increase the hypotensive activities of Terlipressin.Approved, Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Bepridil is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe metabolism of Bepridil can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Bepridil can be increased when combined with Thiopental.Approved, Vet Approved
ThioridazineThe metabolism of Bepridil can be decreased when combined with Thioridazine.Approved
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Bepridil.Approved
TiboloneBepridil may increase the hypotensive activities of Tibolone.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Bepridil.Approved
TiclopidineThe metabolism of Bepridil can be decreased when combined with Ticlopidine.Approved
TicrynafenBepridil may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe serum concentration of Timolol can be increased when it is combined with Bepridil.Approved
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Bepridil.Approved
TipranavirThe serum concentration of Bepridil can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Bepridil.Approved
TolazolineTolazoline may increase the hypotensive activities of Bepridil.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Bepridil is combined with Tolcapone.Approved, Withdrawn
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Bepridil.Approved, Vet Approved
ToloxatoneToloxatone may increase the hypotensive activities of Bepridil.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Bepridil.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Bepridil.Approved, Investigational
TorasemideTorasemide may increase the hypotensive activities of Bepridil.Approved
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Bepridil.Approved, Investigational
TrandolaprilTrandolapril may increase the hypotensive activities of Bepridil.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Bepridil.Experimental
TranylcypromineThe metabolism of Bepridil can be decreased when combined with Tranylcypromine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Bepridil.Approved
TravoprostTravoprost may increase the hypotensive activities of Bepridil.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Bepridil.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Bepridil is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Bepridil.Approved
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Bepridil.Approved, Vet Approved
TrimazosinBepridil may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Bepridil.Approved
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Bepridil.Approved, Investigational
TroleandomycinThe metabolism of Bepridil can be decreased when combined with Troleandomycin.Approved
TylosinThe metabolism of Bepridil can be decreased when combined with Tylosin.Vet Approved
UdenafilUdenafil may increase the antihypertensive activities of Bepridil.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Bepridil.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Bepridil.Approved
UnoprostoneBepridil may increase the hypotensive activities of Unoprostone.Approved
ValsartanValsartan may increase the hypotensive activities of Bepridil.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Bepridil.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Bepridil.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Bepridil.Approved
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Bepridil.Approved
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Bepridil.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Bepridil.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Bepridil.Approved, Investigational
VinpocetineBepridil may increase the hypotensive activities of Vinpocetine.Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Bepridil.Approved
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Bepridil.Approved, Investigational
XylometazolineBepridil may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Bepridil.Approved, Vet Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Bepridil.Approved
ZiprasidoneThe metabolism of Bepridil can be decreased when combined with Ziprasidone.Approved
Food Interactions
  • Alcohol may further decrease blood pressure and increase dizziness and drowsiness
  • Take with food to reduce nausea.
References
Synthesis Reference

Mauvernay, R.Y., Busch, N., Moleyre, J., Monteil, A. and Simond, J.; U.S. Patent 3,962,238;
June 8,1976; assigned to Centre Europeen de Recherches Mauvernay “CERM”.

General ReferencesNot Available
External Links
ATC CodesC08EA02
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9859
Blood Brain Barrier+0.9003
Caco-2 permeable+0.5593
P-glycoprotein substrateSubstrate0.7013
P-glycoprotein inhibitor IInhibitor0.7951
P-glycoprotein inhibitor IIInhibitor0.8387
Renal organic cation transporterInhibitor0.6774
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateNon-substrate0.9117
CYP450 3A4 substrateSubstrate0.5495
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorNon-inhibitor0.8462
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5636
Ames testNon AMES toxic0.67
CarcinogenicityNon-carcinogens0.8688
BiodegradationNot ready biodegradable0.9938
Rat acute toxicity2.4903 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.536
hERG inhibition (predictor II)Inhibitor0.796
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point128Mauvernay, R.Y., Busch, N., Moleyre, J., Monteil, A. and Simond, J.; U.S. Patent 3,962,238; June 8,1976; assigned to Centre Europeen de Recherches Mauvernay "CERM".
water solubilitySlightly solubleNot Available
logP5.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00655 mg/mLALOGPS
logP5.33ALOGPS
logP5.49ChemAxon
logS-4.8ALOGPS
pKa (Strongest Basic)9.16ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area15.71 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity115.12 m3·mol-1ChemAxon
Polarizability43.5 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylmethylamines. These are compounds containing a phenylmethtylamine moiety, which consists of a phenyl group substituted by an methanamine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylmethylamines
Direct ParentPhenylmethylamines
Alternative Parents
Substituents
  • Dialkylarylamine
  • Phenylmethylamine
  • Benzylamine
  • Aralkylamine
  • Aniline
  • N-alkylpyrrolidine
  • Pyrrolidine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Dialkyl ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1A gives rise to P and/or Q-type calcium currents. P/Q-type calcium channels belong to...
Gene Name:
CACNA1A
Uniprot ID:
O00555
Molecular Weight:
282362.39 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Bezprozvanny I, Tsien RW: Voltage-dependent blockade of diverse types of voltage-gated Ca2+ channels expressed in Xenopus oocytes by the Ca2+ channel antagonist mibefradil (Ro 40-5967). Mol Pharmacol. 1995 Sep;48(3):540-9. [PubMed:7565636 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Scaffold protein binding
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1H gives rise to T-type calcium currents. T-type calcium channels belong to the "low-v...
Gene Name:
CACNA1H
Uniprot ID:
O95180
Molecular Weight:
259160.2 Da
References
  1. Cohen CJ, Spires S, Van Skiver D: Block of T-type Ca channels in guinea pig atrial cells by antiarrhythmic agents and Ca channel antagonists. J Gen Physiol. 1992 Oct;100(4):703-28. [PubMed:1281221 ]
  2. Bezprozvanny I, Tsien RW: Voltage-dependent blockade of diverse types of voltage-gated Ca2+ channels expressed in Xenopus oocytes by the Ca2+ channel antagonist mibefradil (Ro 40-5967). Mol Pharmacol. 1995 Sep;48(3):540-9. [PubMed:7565636 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Acts as a regulatory subunit for P/Q-type calcium channel (CACNA1A), N-type (CACNA1B), L-type (CACNA1C OR CACNA1D) and possibly T-type (CACNA1G). Overexpression induces apoptosis.
Gene Name:
CACNA2D2
Uniprot ID:
Q9NY47
Molecular Weight:
129816.095 Da
References
  1. Cohen CJ, Spires S, Van Skiver D: Block of T-type Ca channels in guinea pig atrial cells by antiarrhythmic agents and Ca channel antagonists. J Gen Physiol. 1992 Oct;100(4):703-28. [PubMed:1281221 ]
  2. Bezprozvanny I, Tsien RW: Voltage-dependent blockade of diverse types of voltage-gated Ca2+ channels expressed in Xenopus oocytes by the Ca2+ channel antagonist mibefradil (Ro 40-5967). Mol Pharmacol. 1995 Sep;48(3):540-9. [PubMed:7565636 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hormone binding
Specific Function:
This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates the electrochemical gradient of sodium and potassium ions, providing the energy for active transport of various nutrients.
Gene Name:
ATP1A1
Uniprot ID:
P05023
Molecular Weight:
112895.01 Da
References
  1. Kovacic H, Gallice P, Crevat A: Inhibition of sodium pump by bepridil. An in vitro and microcalorimetric study. Biochem Pharmacol. 1992 Oct 20;44(8):1529-34. [PubMed:1329768 ]
  2. Raess BU, Record DM: Inhibition of erythrocyte Ca2(+)-pump by Ca2+ antagonists. Biochem Pharmacol. 1990 Dec 1;40(11):2549-55. [PubMed:2148481 ]
  3. Smith SJ, England PJ: The effects of reported Ca2+ sensitisers on the rates of Ca2+ release from cardiac troponin C and the troponin-tropomyosin complex. Br J Pharmacol. 1990 Aug;100(4):779-85. [PubMed:2207500 ]
  4. Lamers JM, Cysouw KJ, Verdouw PD: Slow calcium channel blockers and calmodulin. Effect of felodipine, nifedipine, prenylamine and bepridil on cardiac sarcolemmal calcium pumping ATPase. Biochem Pharmacol. 1985 Nov 1;34(21):3837-43. [PubMed:2933041 ]
  5. Fuchs J, Mainka L, Reifart N, Zimmer G: Effects of bepridil on heart mitochondrial membrane and the isolated rat heart preparation. Arzneimittelforschung. 1986 Feb;36(2):209-12. [PubMed:2938592 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function:
Potassium channel that plays an important role in a number of tissues, including heart, inner ear, stomach and colon (By similarity) (PubMed:10646604). Associates with KCNE beta subunits that modulates current kinetics (By similarity) (PubMed:9312006, PubMed:9108097, PubMed:8900283, PubMed:10646604, PubMed:11101505, PubMed:19687231). Induces a voltage-dependent by rapidly activating and slowly ...
Gene Name:
KCNQ1
Uniprot ID:
P51787
Molecular Weight:
74697.925 Da
References
  1. Chouabe C, Drici MD, Romey G, Barhanin J: Effects of calcium channel blockers on cloned cardiac K+ channels IKr and IKs. Therapie. 2000 Jan-Feb;55(1):195-202. [PubMed:10860024 ]
  2. Yumoto Y, Horie M, Kubota T, Ninomiya T, Kobori A, Takenaka K, Takano M, Niwano S, Izumi T: Bepridil block of recombinant human cardiac IKs current shows a time-dependent unblock. J Cardiovasc Pharmacol. 2004 Feb;43(2):178-82. [PubMed:14716203 ]
  3. Chouabe C, Drici MD, Romey G, Barhanin J, Lazdunski M: HERG and KvLQT1/IsK, the cardiac K+ channels involved in long QT syndromes, are targets for calcium channel blockers. Mol Pharmacol. 1998 Oct;54(4):695-703. [PubMed:9765513 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other
General Function:
Troponin t binding
Specific Function:
Troponin is the central regulatory protein of striated muscle contraction. Tn consists of three components: Tn-I which is the inhibitor of actomyosin ATPase, Tn-T which contains the binding site for tropomyosin and Tn-C. The binding of calcium to Tn-C abolishes the inhibitory action of Tn on actin filaments.
Gene Name:
TNNC1
Uniprot ID:
P63316
Molecular Weight:
18402.36 Da
References
  1. Abusamhadneh E, Abbott MB, Dvoretsky A, Finley N, Sasi S, Rosevear PR: Interaction of bepridil with the cardiac troponin C/troponin I complex. FEBS Lett. 2001 Sep 28;506(1):51-4. [PubMed:11591369 ]
  2. Wang X, Li MX, Sykes BD: Structure of the regulatory N-domain of human cardiac troponin C in complex with human cardiac troponin I147-163 and bepridil. J Biol Chem. 2002 Aug 23;277(34):31124-33. Epub 2002 Jun 11. [PubMed:12060657 ]
  3. MacLachlan LK, Reid DG, Mitchell RC, Salter CJ, Smith SJ: Binding of a calcium sensitizer, bepridil, to cardiac troponin C. A fluorescence stopped-flow kinetic, circular dichroism, and proton nuclear magnetic resonance study. J Biol Chem. 1990 Jun 15;265(17):9764-70. [PubMed:2351672 ]
  4. Kleerekoper Q, Liu W, Choi D, Putkey JA: Identification of binding sites for bepridil and trifluoperazine on cardiac troponin C. J Biol Chem. 1998 Apr 3;273(14):8153-60. [PubMed:9525919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Titin binding
Specific Function:
Calmodulin mediates the control of a large number of enzymes, ion channels, aquaporins and other proteins by Ca(2+). Among the enzymes to be stimulated by the calmodulin-Ca(2+) complex are a number of protein kinases and phosphatases. Together with CCP110 and centrin, is involved in a genetic pathway that regulates the centrosome cycle and progression through cytokinesis.
Gene Name:
CALM1
Uniprot ID:
P62158
Molecular Weight:
16837.47 Da
References
  1. Lamers JM, Cysouw KJ, Verdouw PD: Slow calcium channel blockers and calmodulin. Effect of felodipine, nifedipine, prenylamine and bepridil on cardiac sarcolemmal calcium pumping ATPase. Biochem Pharmacol. 1985 Nov 1;34(21):3837-43. [PubMed:2933041 ]
  2. Lamers JM, Verdouw PD, Mas-Oliva J: The effects of felodipine and bepridil on calcium-stimulated calmodulin binding and calcium pumping ATPase of cardiac sarcolemma before and after removal of endogenous calmodulin. Mol Cell Biochem. 1987 Dec;78(2):169-76. [PubMed:2964559 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. Has a preference for cGMP as a substrate.
Gene Name:
PDE1B
Uniprot ID:
Q01064
Molecular Weight:
61379.235 Da
References
  1. Lamers JM, Cysouw KJ, Verdouw PD: Slow calcium channel blockers and calmodulin. Effect of felodipine, nifedipine, prenylamine and bepridil on cardiac sarcolemmal calcium pumping ATPase. Biochem Pharmacol. 1985 Nov 1;34(21):3837-43. [PubMed:2933041 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. Has a higher affinity for cGMP than for cAMP.
Gene Name:
PDE1A
Uniprot ID:
P54750
Molecular Weight:
61251.38 Da
References
  1. Lamers JM, Cysouw KJ, Verdouw PD: Slow calcium channel blockers and calmodulin. Effect of felodipine, nifedipine, prenylamine and bepridil on cardiac sarcolemmal calcium pumping ATPase. Biochem Pharmacol. 1985 Nov 1;34(21):3837-43. [PubMed:2933041 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Ibrahim S, Peggins J, Knapton A, Licht T, Aszalos A: Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation. J Pharmacol Exp Ther. 2000 Dec;295(3):1276-83. [PubMed:11082465 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 08, 2016 11:47